Inovio Pharmaceuticals, Inc.INO

INOVIO Pharmaceuticals’ latest 10-Q (period ending 31 March 2026) shows the company booked zero revenue while burning $19.7 million of net income and $21.6 million of operating cash, leaving shareholders staring at a $6.1 million equity buffer and a working thesis that still awaits its first paying customer. The cash balance stood at $26.3 million, but $11.4 million of that was tucked into short-term investments-corporate mattress-stuffing that keeps headline cash pretty but does not pay for the next trial. The company’s DNA-medicine platform promises plasmids engineered like software to instruct cells to manufacture therapeutic proteins, yet the income statement has not recorded a single dollar of product revenue. Instead, the quarterly filing confirms $14.1 million of R&D expense and $0 revenue, a combination that translates to a diluted loss of 28 cents per share on 69.1 million diluted shares outstanding.

INOVIO’s product story hinges on INO-3107, a single candidate pitched as a potential preferred treatment for a targeted indication; the July 2 2026 S-3 filing notes that FDA accelerated-approval discussions could occur as early as August 2025 and that the company believes the completed trial data may support a Biologic License Application under the accelerated approval pathway. The filing reads like a biotech version of “send more money and maybe something ships,” because the document also confirms that the company has not yet generated commercial revenue. Meanwhile, INOVIO’s S-8 filed 26 May 2026 registers a new employee benefit plan, and the S-3 shelf is priced at $100 million-a registration statement that allows the company to issue shares when it likes rather than when the product likes. The platform page still features the same DNA plasmid graphic, but the actual filing pages show a company that has not yet crossed the revenue line.

According to the 10-Q, total assets were $49.8 million against liabilities of $43.7 million, producing shareholders’ equity of $6.1 million as of 31 March 2026. Cash and cash equivalents were $26.3 million, with $11.4 million in short-term investments, giving a headline cash headline that obscures the fact that the operating cash used in the quarter was $21.6 million. Research and development expense for the quarter was $14.1 million, and the company reported a net loss of $19.7 million, or $0.28 per diluted share on 69.1 million diluted shares outstanding. Property, plant, and equipment additions were zero, and the company made no filings disclosing revenue from customers. The company’s DNA Medicines Technology page explains that INOVIO designs DNA plasmids-small circular DNA molecules-to act like software that cells can read to produce proteins that fight disease, and that proprietary delivery technology aims to get the plasmids inside the cell. The product page is vivid, but the 10-Q is blunt: no revenue, rising losses, and a balance sheet that funds runway rather than products.

The SEC submissions JSON for CIK 0001055726 lists the company facts API endpoint, the submissions feed, and the EDGAR index, confirming that the only publicly available financials remain those in the 10-Q for the quarter ended 31 March 2026. The company’s news releases page lists corporate announcements, but none in the evidence set record revenue or an FDA approval. The shareholder services page provides administrative contact details, not financial metrics. In short, the current filings show a pre-revenue biotech whose near-term value lever is a single candidate’s regulatory outcome and whose cash position is comfortable only because management has chosen to invest a material share of existing cash in short-term securities rather than deploy it against near-term cash-burn needs.

If you need a chart, the company’s shares trade on the OTC Markets under INO, ticker INO, venue OTCQB; the evidence set does not supply price, volume, or market-cap data, so any attempt to draw levels here would be invention. The company’s own platform materials and product pages are visually polished but numerically unsupported by the filed accounts, which remain the only source of verifiable financial data. The tension in the file is therefore simple: the story is about a single product’s chance to accelerate to market while the company’s cash runway is extended by paper gains parked in short-term investments rather than spent on trials or commercial build-out.